• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
1AD

ADALTA LIMITED

0.00% ! 0.4¢
Market Cap $11.90M  !
Healthcare Biotechnology
Add to My Watchlist

AdAlta Limited is an Australia-based drug discovery and development company. The Company... AdAlta Limited is an Australia-based drug discovery and development company. The Company is focused on using its technology platform to generate protein therapeutics, known as i-bodies, for treating a range of human diseases. The Company's principal activity is to develop its ibody platform with a focus on its lead candidate AD-114, a treatment for idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Its i-body AD-114 drug candidate is used for treatment in various fibrosis related eye diseases to support the pre-clinical development of the eye fibrosis indication. The Company's AD-114 has shown both anti-fibrotic and anti-inflammatory effects in various animal models. The Company's AD-114 is used in various therapeutic applications for fibrosis diseases of the liver, skin, kidney and heart. AD-114 has completed pre-clinical studies in vitro (in the lab) and in vivo (in animals) data obtained.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits

Latest Threads

Tag Subject Date Created with Sketch. Comments Created with Sketch. Views Created with Sketch.
1AD
Ann: AdAlta presenting at 3rd ANZ Biologics Festival 		04/02/25 0 1
04/02/25 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  1 
1AD
Ann: Investor Presentation 		24/04/18 4 605
24/04/18 Last post  Anton Chigurh Comments Created with Sketch.  4  Views Created with Sketch.  605 
1AD
Ann: Appendix 4C - Quarter Ended 31 March 2018 		23/04/18 0 73
23/04/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  73 
1AD
Ann: Interview AdAlta CEO AD-214 		18/04/18 0 86
18/04/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  86 
1AD
Ann: Shareholder information sessions 		18/04/18 0 63
18/04/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  63 
1AD
Ann: Investor presentation 		18/04/18 0 76
18/04/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  76 
1AD
Ann: AdAlta to advance improved lung fibrosis therapy, AD-214 		18/04/18 0 87
18/04/18 Last post  ASX News Comments Created with Sketch.  0  Views Created with Sketch.  87 
1AD
Interesting looking stock 		08/03/18 27 11K
08/03/18 Last post  hamsa Comments Created with Sketch.  27  Views Created with Sketch.  11K 

See All Discussions arrow Created with Sketch.

Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
Add to My Watchlist
Start T rading
Last
0.4¢ 		Change
0.000(0.00%) 		Mkt cap ! $11.90M
Open High Low Volume
0.4¢ 0.4¢ 0.4¢ 26.07K

Buyers (Bids)

Vol. Price($)
26862664 0.3¢
 

Sellers (Offers)

Price($) Vol.
0.4¢ 9010137
Last trade - 09.59am 28/07/2026 (20 minute delay) ?
1AD (ASX) Chart

Top Stories

Diablo expands critical minerals footprint at Star Range

Welcome to HotCopper’s latest Watchlist, where this week we’ve been joined by Diablo Resources (ASX:DBO) CEO Lyle Thorne to discuss recent exploration that’s @expanded the scale” at Star Range in Beaver County, Utah.Listen to t...
Expert Exchange: The Kouk on Michelle Bullock's legacy as RBA Governor Economist Stephen Koukoulas breaks down Michele Bullock's RBA legacy so far and what her final years as Governor could mean for Aussies.
Prairie Lithium advances towards first production as commercial DLE unit arrives Prairie Lithium (ASX:PL9) has reached a major milestone in its path to first production, with North America’s largest commercial Direct Lithium Extraction (DLE) unit now delivered to site in Saskatchewan. The arrival marks the start of installation as the ASX-listed company moves ...
AFT Pharmaceutical's multi-billion R&D opportunity Welcome to HotCopper’s latest Watchlist, where we’ve been joined by AFT Pharmaceuticals (ASX:AFP) founder and chief executive Hartley Atkinson to discuss its expanding global reach and the @tentative” FDA approval the company has just hauled i...
Klevo Rewards advances stablecoin strategy with credit licence acquisition Klevo Rewards CEO Alexander Gold talks to HotCopper about officially completing the acquisition of an Australian credit licence.
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.